耐药相关基因在卵巢癌组织中的表达及其临床意义  

The Expression of Multiple Drug Resistance Associated Genes in Ovarian Cancer

作　　者：程国钧[1] 祝华 孙丽亚[2] 李亚里[1] 李春海[2] 杨秀玉[3] 

机构地区：[1]解放军总医院妇产科,北京100853 [2]军事医学科学院 [3]中国医学科学院

出　　处：《中华妇产科杂志》2000年第2期87-90,共4页Chinese Journal of Obstetrics and Gynecology

摘　　要：目的　通过测定多药耐药基因 (MDR1)、多药耐药相关蛋白 (MRP)、肺耐药相关蛋白(LRP)和谷胱甘肽S 转移酶 (GST π)在卵巢癌组织中的表达 ,了解其在卵巢癌化学治疗耐药中的作用。方法　采用逆转录 聚合酶链反应 (RT PCR)测定了 41例卵巢癌、2 5例良性卵巢肿瘤和 12例正常卵巢组织中MDR1、MRP、LRP和GST π的表达 ,并分析其与临床、病理特征的关系。结果　 (1)在正常卵巢、良性卵巢肿瘤和卵巢癌组织中 ,MDR1的阳性表达率分别为 0 .0 %、0 .0 %和 2 9.3% ;MRP阳性表达率分别为 16 .7%、12 .0 %和 5 3.7% ;LRP阳性表达率分别为 2 5 .0 %、5 2 .0 %和 87.8% ;GST π阳性表达率分别为 8.3%、12 .0 %和 5 1.2 %。上述 4项指标在卵巢癌组织中的表达均明显高于正常卵巢和良性卵巢肿瘤组织 (P <0 .0 5 )。(2 )耐药基因在卵巢癌组织中的共同表达现象明显多于良性卵巢肿瘤和正常卵巢 (P <0 .0 5 )。 (3)临床Ⅲ～Ⅳ期卵巢癌组织中 ,MDR1和MRP的阳性表达率分别为 33.3%和 6 0 .6 % ,高于临床Ⅰ～Ⅱ期 (Ⅰ期 8例中 1例 ,Ⅱ期 8例中 2例 ) ,但差异无显著性 (P >0 .0 5 )。不同期别的卵巢癌组织中LRP和GST π的阳性表达率相近 (P >0 .0 5 )。(4)MDR1、MRP、LRP和GST π的表达与肿瘤病理类型无关 (P >0 .0 5 )。 (5 )Objective The aim of the investigation was to find out the relationship between the expression of multidrug resistance gene (MDR1), multidrug resistance protein (MRP), lung resistance protein (LRP) and glutathione S transferase pi(GST π) with the clinical pathological characteristics and the prognosis in the ovarian cancer patients who never received chemotherapy before operation. Methods The expression of MDR1, MRP, LRP and GST π in 41 cases of ovarian cancer, 25 cases of benign ovarian tumor and 12 normal ovary tissue were investigated by reverse transcription polymerase chain reaction(RT PCR). Results In normal ovary, benign tumor and ovarian cancer, the positive expression of MDR1 was 0.0%, 0.0% and 29.3%, the positive of MRP was 16.7%、12.0% and 53.7%, the positive of LRP was 25.0%、52.0% and 87.8%, the positive of GST π was 8.3%、12.0% and 51.2% respectively. The ratios of co expression of multiple genes in ovarian cancer were much higher than that in benign ovarian tumor. All tested genes showed no significant relationship to the clinical stage, histological type and the differentiation of the tumor except that the expression of MDR1 and MRP was closely related to the differentiation ( P <0.05). The non responders to platinum or taxol based combination chemotherapy exhibited higher ratios of MDR1 and MRP expression than the responders ( P <0.05). Furthermore, the co expression phenomenon was more common in non responders. Conclusions Multiple gene expression is involved in drug resistance in ovarian cancer. The co expression of MDR1, MRP, LRP and GST π is higher in ovarian cancer than that in benign ovarian tumor and normal ovary tissue. The expression of MDR1 and MRP is closely related to the tumor differentiation and the response to chemotherapy.

关 键 词：卵巢肿瘤 LRP GST-Π MDR1 MRP 

分 类 号：R737.31[医药卫生—肿瘤]